Your browser doesn't support javascript.
Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine.
Agrati, Chiara; Castilletti, Concetta; Goletti, Delia; Sacchi, Alessandra; Bordoni, Veronica; Mariotti, Davide; Notari, Stefania; Matusali, Giulia; Meschi, Silvia; Petrone, Linda; Aiello, Alessandra; Najafi Fard, Saeid; Farroni, Chiara; Colavita, Francesca; Lapa, Daniele; Leone, Sara; Agresta, Alessandro; Capobianchi, Maria; Ippolito, Giuseppe; Vaia, Francesco; Puro, Vincenzo.
  • Agrati C; INMI L.Spallanzani-IRCCS, Via Portuense 292, 00149, Rome, Italy.
  • Castilletti C; INMI L.Spallanzani-IRCCS, Via Portuense 292, 00149, Rome, Italy.
  • Goletti D; INMI L.Spallanzani-IRCCS, Via Portuense 292, 00149, Rome, Italy.
  • Sacchi A; INMI L.Spallanzani-IRCCS, Via Portuense 292, 00149, Rome, Italy.
  • Bordoni V; INMI L.Spallanzani-IRCCS, Via Portuense 292, 00149, Rome, Italy.
  • Mariotti D; INMI L.Spallanzani-IRCCS, Via Portuense 292, 00149, Rome, Italy.
  • Notari S; INMI L.Spallanzani-IRCCS, Via Portuense 292, 00149, Rome, Italy.
  • Matusali G; INMI L.Spallanzani-IRCCS, Via Portuense 292, 00149, Rome, Italy.
  • Meschi S; INMI L.Spallanzani-IRCCS, Via Portuense 292, 00149, Rome, Italy.
  • Petrone L; INMI L.Spallanzani-IRCCS, Via Portuense 292, 00149, Rome, Italy.
  • Aiello A; INMI L.Spallanzani-IRCCS, Via Portuense 292, 00149, Rome, Italy.
  • Najafi Fard S; INMI L.Spallanzani-IRCCS, Via Portuense 292, 00149, Rome, Italy.
  • Farroni C; INMI L.Spallanzani-IRCCS, Via Portuense 292, 00149, Rome, Italy.
  • Colavita F; INMI L.Spallanzani-IRCCS, Via Portuense 292, 00149, Rome, Italy.
  • Lapa D; INMI L.Spallanzani-IRCCS, Via Portuense 292, 00149, Rome, Italy.
  • Leone S; INMI L.Spallanzani-IRCCS, Via Portuense 292, 00149, Rome, Italy.
  • Agresta A; INMI L.Spallanzani-IRCCS, Via Portuense 292, 00149, Rome, Italy.
  • Capobianchi M; INMI L.Spallanzani-IRCCS, Via Portuense 292, 00149, Rome, Italy.
  • Ippolito G; INMI L.Spallanzani-IRCCS, Via Portuense 292, 00149, Rome, Italy. giuseppe.ippolito@inmi.it.
  • Vaia F; INMI L.Spallanzani-IRCCS, Via Portuense 292, 00149, Rome, Italy.
  • Puro V; INMI L.Spallanzani-IRCCS, Via Portuense 292, 00149, Rome, Italy.
Sci Rep ; 12(1): 6687, 2022 04 23.
Article in English | MEDLINE | ID: covidwho-1805648
ABSTRACT
Vaccine is the main public health measure to reduce SARS-CoV-2 transmission and hospitalization, and a massive scientific effort worldwide resulted in the rapid development of effective vaccines. This work aimed to define the dynamics and persistence of humoral and cell-mediated immune response in Health Care Workers who received a two-dose BNT162b2-mRNA vaccination. Serological response was evaluated by quantifying anti-RBD and neutralizing antibodies while cell-mediated response was performed by a whole blood test quantifying Th1 cytokines (IFN-γ, TNF-α, IL-2) produced in response to Spike peptides. BNT162b2-mRNA vaccine induced both humoral and cell-mediated immune response against Spike in all HCW early after the second dose. After 12 weeks from vaccination, the titer of anti-RBD antibodies as well as their neutralization function decreased while the Spike-specific T-cells persisted at the same level as soon after vaccine boost. Of note, a correlation between cellular and humoral response persevered, suggesting the persistence of a coordinated immune response. The long lasting cell-mediated immune response after 3 months from vaccination highlight its importance in the maintaining of specific immunity able to expand again to fight eventual new antigen encountering.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies Topics: Vaccines Limits: Humans Language: English Journal: Sci Rep Year: 2022 Document Type: Article Affiliation country: S41598-022-07741-z

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies Topics: Vaccines Limits: Humans Language: English Journal: Sci Rep Year: 2022 Document Type: Article Affiliation country: S41598-022-07741-z